Oncorus is a pre-clinical stage biotechnology company developing innovative and impactful, next-generation oncolytic HSV products with unprecedented potential to recruit all arms of immune system to treat solid tumors.
The Oncorus family is dedicated to bringing hope and impactful therapies to cancer patients everywhere. As part of our commitment, we have taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
The Oncorus family is dedicated to bringing hope and impactful therapies to cancer patients everywhere. As part of our commitment, we have taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $141.99M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | SV Investm... | svinvest.c... |
| - | K2 HealthV... | k2healthve... |
| - | BioImpact ... | bioimpactc... |
| - | Perceptive... | perceptive... |
| - | UTC Invest... | utc.co.kr |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.08.2019 | Series B | $80M | Perceptive... |
| 16.12.2016 | Series A | $4.99M | - |
| 20.07.2016 | Series A | $57M | - |
Mentions in press and media 17
| Date | Title | Description |
| 05.04.2022 | Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway | -Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a GMP-compliant manufacturing facility in Andover, MA and the clinical development of its IV ad... |
| 27.05.2021 | ONCORUS, INC. Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788 | Pioneering Synthetic vRNA immunotherapies that are composed of self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid nanoparticles (LNPs) Novel approach engineered to produce a living immunostimulatory drug in the fo... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Funding | CAMBRIDGE, MA, Oncorus today announced the completion of an oversubscribed $79.5 million Series B financing. >> Click here for more funding data on Oncorus >> To export Oncorus funding data to PDF and Excel, click here On... |
| 21.08.2019 | Oncorus Announces $79.5 Million Series B Financing to Support the Advancement of Oncolytic Virus Therapies to Transform Outcomes for Cancer Patients | - |
| 21.08.2019 | Oncorus Raises $79.5M Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving innovation to transform outcomes for cancer patients, today announced the completion of an oversubscribed $79.5 million Series B financing. Cowe... |
| 21.08.2019 | Oncorus raises $80M for 2-front oncolytic virus R&D push | Oncorus has raised $79.5 million to advance oncolytic viruses. The series B round equips Oncorus to move its lead prospect into the clinic and nominate an intravenously administered viral candidate early next year. That second, intravenous ... |
| 21.08.2019 | Oncorus raises $80M for 2-front oncolytic virus R&D push W h i t e p a p e r Weighing the Costs: | Oncorus has raised $79.5 million to advance oncolytic viruses. The series B round equips Oncorus to move its lead prospect into the clinic and nominate an intravenously administered viral candidate early next year. Sponsored by Agilent Tech... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving innovation to transform outcomes for cancer patients, today announced the completion of an oversubscribed $79.5 million Series B financing. Cowe... |
| 21.08.2019 | Oncorus Announces $79.5 Million Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors | –Company advancing broad pipeline of next-generation oncolytic virus therapies for both intratumoral and intravenous administration for multiple solid tumor indications– –Novel innovations to enhance potency and safety enable best-in-class ... |
| 21.08.2019 | Oncorus Raises $79.5M in Series B Financing | Oncorus, Inc., a Cambridge, Mass.-based oncolytic virus company, closed a $79.5m Series B financing. The round was co led by Cowen Healthcare Investments and Perceptive Advisors, with participation from Oncorus’ syndicate of Series A invest... |
Show more